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Dietary fiber-derived short-chain fatty acids (SCFA) and phenolics produced by the gut microbiome have multiple effects on health. We have tested the
hypothesis that long-term exposure to physiological concentrations of SCFA can affect the transport and metabolism of (poly)phenols by the intestinal
epithelium using the Caco-2 cell model. Metabolites and conjugates of hesperetin (HT) and ferulic acid (FA), gut-derived from dietary hesperidin and chlorogenic
acid, respectively, were quantified by LC-MS with authentic standards following transport across differentiated cell monolayers. Changes in metabolite levels
were correlated with effects on mRNA and protein expression of key enzymes and transporters. Propionate and butyrate increased both FA transport and rate of
appearance of FA glucuronide apically and basolaterally, linked to an induction of MCT1. Propionate was the only SCFA that augmented the rate of formation of
basolateral FA sulfate conjugates, possibly via basolateral transporter up-regulation. In addition, propionate enhanced the formation of HT glucuronide
conjugates and increased HT sulfate efflux toward the basolateral compartment. Acetate treatment amplified transepithelial transport of FA in the apical to
basolateral direction, associated with lower levels of MCT1 protein expression. Metabolism and transport of both HT and FA were curtailed by the organic acid
lactate owing to a reduction of UGT1A1 protein levels. Our data indicate a direct interaction between microbiota-derived metabolites of (poly)phenols and SCFA
through modulation of transporters and conjugating enzymes and increase our understanding of how dietary fiber, via the microbiome, may affect and enhance
uptake of bioactive molecules.
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The gut microbiome-nutrition-obesity axis has become a key focus
of recent translational research and accumulating studies show that
microbial metabolites are important regulators of the intestinal
epithelial barrier, shaping gut immunity [1]. The gut is host to more
than 100 trillion cells and 5 million unique genes coding for enzymes
that ferment dietary ﬁber to large quantities of short-chain fatty acids
(SCFA), the preferential source of energy for colonocytes [1–3]. The
ratio of themain SCFAs, acetate, propionate and butyrate, is altered by
consumption of prebiotics and certain drugs [3–6]. Several health
beneﬁts have been proposed for SCFA, including prevention of
intestinal inﬂammation, reduction of colon cancer risk, stimulation
of satiety and hypolipidemic effects [3,7–10]. Lactate, another
microbial product resulting from the fermentation of dietary polysac-
charides, is found at lower concentrations than SCFA as it is further
oxidized by cross-feeding but can still reach 5 mM in the gut lumen of
healthy individuals [11]. The MCT1 transporter is mainly responsible
for absorption of luminal SCFA [12–15] in colonocytes and is also
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SCFA can also modulate transporter expression and, for example,
enhance MCT1 function as shown in several intestinal cell models
[12,18,19]. In pig colon, resistant starch consumption raised SCFA
concentrations in the gut, followed by an up-regulation of MCT1 [4],
while MCT1 expression was increased in the rat intestine after pectin
feeding, althoughno datawere reported regarding SCFA content in the
gut [20]. These studies indicate that diet can inﬂuence SCFA
production in the gut and promote their uptake by regulation of
transporter expression in the gut epithelium.
Polyphenols are a broad class of compounds, including mono-
phenolic hydroxycinnamic acids and multiphenolic ﬂavonoids, and
will be referred to here as (poly)phenols. They have biological effects
on health biomarkers in humans, sometimes dependent both on
bioavailability and on microbial metabolism [21–23]. Some of the
transporters involved in (poly)phenol bioavailability are also involved
in SCFA absorption, giving rise to the possibility of interactions
between these two classes in absorption and metabolism.
Hesperidin is the main (poly)phenol in sweet oranges. Due to an
attached rutinose moiety, it passes through the small intestine
unchanged to the colon [24], where combined activity of bacterial
α-rhamnosidases and β-glucosidases release the aglycone hesperetin
(HT) [25,26]. HT can be absorbed by passive transcellular diffusion, but
its phase II metabolites are more hydrophilic and require active
transport. Hesperetin-7-O-glucuronide (HT-7-glu), hesperetin-7-O-
sulfate (HT-7-sul) and, to a lesser extent, hesperetin-3′-O-glucuronide
(HT-3′-glu) interact with apically expressed ABCG2 while both
glucuronides can interact with ABCC2 and basolateral ABCC3 [27,28].
Information on deﬁnitive interactions of HT-sul with efﬂux trans-
porters is less convincing, possibly with efﬂux of HT-7-sul by ABCG2,
but this remains debatable [27,29].
Hydroxycinnamic acids such as caffeic acid (in chlorogenic acid)
are found in coffee and metabolized to ferulic acid (FA) in the colon.
Similarly, FA in cereals and whole grain products is covalently bound
to the indigestible cellwall polysaccharides in planta [30] and becomes
bioaccessible only when released from the food matrix by esterase
activity of the intestinal microbiota [31,32]. In intestinal cells, FA is
partly absorbed via MCT1 and MCT4 [18,33] and undergoes glucur-
onidation by UGT1A1 isoforms [34]. Sulfation of FA by SULT1E1 and,
to a lesser extent, by SULT1A1, an isoform particularly abundant
in Caco-2 cells [34,35], has been previously reported. However, the
exact transporters for FA conjugates are not yet known as ABCC2
(MRP2) and ABCG2 do not interact with phenolic sulfates or
glucuronides [36].
To further our mechanistic understanding of the effect of SCFA
on absorption of (poly)phenols, we used differentiated Caco-2
cell monolayers grown on permeable supports in a two-pronged
approach: to investigate how long-term exposure of cells to SCFA
and lactate could affect intestinal transformation and transport of
two dietary gut-derived abundant bioactives (FA and HT) and to
link this to changes in key shared transporters (MCT1, MCT4 and
ABCG2) and detoxiﬁcation systems (UGT1A) to explain the observed
changes.
2. Materials and methods
2.1. Cell culture
Caco-2 cells were obtained from ATCC (ATCC-HTB37; LGC Standards, Teddington,
Middlesex, UK) and maintained in Dulbecco's modiﬁed Eagle's medium containing
4.5 g/L glucose supplemented with 2% GlutaMAX (GIBCO, Life Technologies, Thermo
Fisher Scientiﬁc, Paisley, UK), 1% nonessential amino acids, 1% sodium pyruvate, 1%
penicillin/streptomycin and 10% heat-inactivated fetal bovine serum (FBS). Cells were
kept in a humidiﬁed atmosphere at 37°C and 10% CO2 in T75 ﬂasks (Corning 430641;
AppletonWoods, Birmingham, UK). Mediumwas changed every other day and cultures
were passaged at 70–90% conﬂuency using trypsin–EDTA (0.25%). All cell culture
reagents were from Sigma (Sigma Aldrich, Gillingham, UK) unless otherwise stated.2.2. Experimental conditions
Caco-2 cells were seeded on 6-well transwell dishes (Corning 3412; Appleton
Woods, UK) at a density of 6×104 cm−2 and maintained for 21–23 days. From day 7
postseeding, the medium in the apical compartment was depleted of FBS and
supplemented with a ﬁnal concentration of 1 mM Na-acetate, Na-propionate, Na-
butyrate or Na-lactate or an equimolar mixture of these four compounds (0.25 mM
each, total concentration of 1 mM). FBS in the basal compartment medium was
increased to 20% to mimic intestinal conditions. Stocks of SCFA were prepared in 25%
DMSO resulting in a ﬁnal concentration of 0.1% DMSO, whichwas used as control. High-
purity (18.2 MΩ cm−1) water supplied by a MilliQ system (Merck Millipore UK,
Watford, UK) was used throughout this work.
2.3. Immunofluorescence
For immunostaining, Caco-2 cells were seeded on 12-well Millicell culture dishes
(MCHT12H48; Merck Millipore) and allowed to grow as described in Section 2.2. After
21–23 days, cells were washed with ice-cold PBS, ﬁxed with 4% paraformaldehyde in
PBS for 15 min and incubated with ﬂuorescein-labeled wheat germ agglutinin (Vector
Laboratories, Peterborough, UK) for 10 min. Cells were permeabilized with 0.1% Triton
X-100 and incubated with MCT1 (sc-365501; Santa Cruz Biotechnology, Insight
Biotechnology, Middlesex, UK), MCT4 (sc-376139; Santa Cruz Biotechnology, Insight
Biotechnology) or ABCG2 (NBP1-59749; NovusAntibodies, Bio-Techne, Cambridge, UK)
antibodies at a dilution of 1:15 for MCT1 and MCT4 and 1:50 for ABCG2 for 1 h at room
temperature. Afterwashingwith PBS, cells were further incubatedwith Cy3-conjugated
donkey antimouse IgG (MCTs) or antirabbit IgG (ABCG2) (Jackson ImmunoResearch,
West Grove, Pennsylvania, USA) at a 1:300 dilution. Nuclei were stained using 2 μg/ml
DAPI and Millicell ﬁlters were removed with a scalpel and mounted on microscopy
slides with ProLong Gold antifade reagent (Molecular Probes, Thermo Fisher Scientiﬁc,
Paisley, UK). A similar protocol was followed for detection of tight junctions, using
Claudin 1 rabbit antibody (ab180158; Abcam, Cambridge, UK) at 1:400 and Alexa488-
conjugated antirabbit IgG (Jackson ImmunoResearch) at 1:300 dilution. Cell images
were obtainedwith a Zeiss LSM700 inverted confocalmicroscopewith a 63× (NA1.4) or
40× (NA 1.3) objective.
2.4. Gene expression analysis by ddPCR
Caco-2 cells were seeded on 6-well transwell dishes and treated as described in
Section 2.2. On days 21–23, cells were washed with ice-cold PBS, scraped from ﬁlters,
and mRNA was extracted using the Ambion RNAqueous kit (AM1912; Ambion, Life
Technologies, Thermo Fisher Scientiﬁc), according to the manufacturer's protocol. One
microgram of RNAwas transcribed to cDNA using the Applied Biosystems high-capacity
RNA to cDNA kit (4387406; Life Technologies, Thermo Fisher Scientiﬁc). The QX100
Droplet Digital PCR system (ddPCR; BioRad Laboratories, Hercules, CA, USA)was used to
quantify changes in gene expression of MCT1, MCT4 and ABCG2 from four biological
replicates from two seeding experiments (total, n=4), with three technical replicates
each. Each assay (20 μl) consisted of reaction mix prepared with 0.65 ng of transcribed
cDNA diluted with MilliQ water to 9 μl; 1 μl of FAM-labeled TaqMan primer of MCT1,
MCT4 or ABCG2; 1 μl of VIC-labeled TaqMan primer of TBP (TATA box binding protein)
(all from Life Technologies, Thermo Fisher Scientiﬁc); and 10 μl ddPCR Supermix for
Probes (No dUTP) (BioRad Laboratories UK, Hemel, Hertfordshire, UK). PCR mixture-
containing droplets were generated according to manufacturer's guidelines with the
QX100 droplet generator before cycling in a C1000 touch thermal cycler (BioRad
Laboratories, Hercules, CA, USA) at optimal annealing/extension temperature for every
primer. On average, ddPCR yielded 16,103±1148 (standard deviation) accepted
droplets per well. Data from the QX100 Droplet Reader were analyzed with the
QuantaSoft software (Kosice, Slovakia). Concentration of the target DNA in copies per
microliter was calculated from the fraction of positive reactions using Poisson
distribution analysis. Results shown represent total copies of each transporter and of TBP
per nanogram of cDNA. All reactions were performed in duplex mode. The ddPCR data for
each target gene are collected independently basedonﬂuorescence signal and copynumbers
are reported for all. Therefore, thehousekeeping gene expression can bemonitoredbut is not
necessary for data evaluation. Although multiplexing with TBP was intended as a
housekeeping gene, small changes in copy number were observed and these are also
reported here. The Applied Biosystems ID of the primer/probe set for MCT1 (SLC16A1) was
Hs00161826_m1, that for MCT4 (SLC16A3) was Hs00358829_m1, that for ABCG2 was
Hs01053790_m1 and that for TBP was Hs00427620_m1.
2.5. Protein analysis — Simple Western immunoassays
For protein detection, Caco-2 cells were grown on 6-well transwell dishes as
described in Section 2.2. At 21–23 days, cells were washed with ice-cold PBS, scraped
and lysed in Bicine-CHAPS buffer (ProteinSimple, San Jose, CA, USA) containing 1%
protease (P8340) and 1% phosphatase inhibitor cocktail (P0044 and P5762) (Sigma
Aldrich). The lysate was centrifuged at 14,000g for 10 min at 4°C and the total protein
concentration of the supernatant was determined by BCA microplate assay (Pierce
Biotechnology, Thermo Fisher Scientiﬁc) according to manufacturer's instructions.
MCT1, MCT4, ABCG2 and UGT1A protein abundance was determined using the
ProteinSimple system “WES” (Bio-Techne, ProteinSimple) according to manufacturer's
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incubation with DTT and SDS-containing Master Mix (Bio-Techne, ProteinSimple) at
37°C for 20min. Because of differences in compatibility of antibodieswhenmultiplexing
and denaturing condition requirements for the individual protein targets, different
loading controls were tested and selected for each protein of interest. Claudin 1, a tight
junction marker (1:50, mouse monoclonal, #37-4900; Invitrogen, Life Technologies,
Thermo Fisher Scientiﬁc) was used as a loading control and run in the same capillary as
MCT1 (1:25, mouse monoclonal, sc-365501; Santa Cruz Biotechnology, Insight
Biotechnology) and MCT4 (1:25, mouse monoclonal, sc-376139; Santa Cruz Biotech-
nology, Insight Biotechnology). For ABCG2 determination, α-tubulin (1:50, rabbit
monoclonal, 2125S; Cell Signalling Technology, New England Biolabs, Hertfordshire,
UK) was used as a loading control and detected from the same sample run in separate
capillaries (1:50, rabbit polyclonal NBP1-59749; Novus Antibodies, Bio-Techne).
Denaturation was carried out by incubation for 5 min at 95°C. Claudin 1 (1:50, rabbit
monoclonal, ab180158; Abcam, Cambridge, UK) was also used as loading control for
UGT1A (1:50, rabbit polyclonal, sc-25847; Santa Cruz Biotechnology, Insight Biotech-
nology) and both run in the same capillary. All antibodies were used in the linear
response range following optimization (Fig. A.3). Quantiﬁcation of peak areas and gel
image reconstruction was carried out using the ProteinSimple Compass software. Every
sample including the biotinylated ladder contained three ﬂuorescent molecular weight
standards that were used to align each individual capillary with the ladder and assign
the molecular weights to detected peaks.
2.6. Transport experiments
For transport experiments, Caco-2 cells were grown on 6-well transwell dishes as
described in Section 2.2. At 21–23 days, cells were washed twice with Hank's Balanced
Salt Solution (HBSS) containing 1.8mMCaCl2 at pH 7.4 and allowed to equilibrate for 30
min in a humidiﬁed atmosphere at 37°C and 10% CO2. Monolayer integrity was
determined by the Transepithelial Electrical Resistance (TEER) of the cell layer
measured with the Millicell ERS voltohmmeter (Merck Millipore UK) and, at the
same stage, cell differentiation was also conﬁrmed by Claudin 1 staining of tight
junctions in separately seeded dishes (Fig. A.2). Monolayers with a TEER value lower
than 930Ω cm2were discarded. HBSS was aspirated and 2 ml fresh HBSS was added to
the basal compartment for the transport experiment. In the apical compartment, 2 ml
HBSS containing 20 μM HT, 500 μM FA or 1 mM salicylic acid (SA) was added. SA was
used as a positive control for MCT-dependent transport [37]. After 30 min (SA) or 1 h
(HT or FA) incubation, TEER values were measured again to conﬁrm sustained
monolayer integrity. Incubation times were chosen according to previous transport
experiments reported in the literature for these compounds. A total of 500 μl aliquots of
media were collected from both compartments and ascorbic acid was added to 100 μM.
Samples were then stored at−80°C until further analysis.
2.7. LC-MS/MS analysis
HT and FAmetabolites were analyzed by high-performance liquid chromatography
(HPLC) mass spectrometry. Separation was carried out on a Phenomenex Kinetex
XB C18, 2.1×100 mm, 2.6 μm column (Phenomenex, Cheshire, UK) set to 35°C. Solvent
A was 5% acetonitrile in MilliQ water containing 0.1% formic acid, and solvent
B was 5% MilliQ water in acetonitrile containing 0.1% formic acid. All solvents
were ofmass spectrometry grade (VWR, Leicestershire, UK). Flow ratewas 0.25ml/min,
and injection volume was 10 μl. The HPLC system (Agilent 1200 series; Agilent
Technologies, Waldbronn, Germany) was coupled to an Agilent 6410 ESI-MS/MS
(Agilent Technologies, Santa Clara, CA, USA) set to negative ion mode and multiple
reaction monitoring (MRM) scanning was applied to quantify compounds. Fragmentor
voltages and collision energies were optimized for each compound using pure standard
solutions.
Daidzein, 3,4-dimethoxycinnamic acid (DMCA), ascorbic acid, dihydroferulic acid
(DHFA), HT and FA were purchased from Sigma (Sigma Aldrich). Ferulic acid-4-O-
sulfate (FA-sul) was synthesized by Dr. Nicolai U. Kraut (University of Leeds, Leeds, UK),
FA and HT glucuronides were kindly provided by Prof. Denis Barron (Nestlé Institute of
Health Sciences, Lausanne, Switzerland) and hesperetin-3′-O-sulfate (HT-3′-sul) was a
gift from Dr. Christine Morand (INRA, Human Nutrition Unit, France). Quantiﬁcation
was based on a 6-level matrix matched calibration and peak areas were normalized to
the peak area of the internal standard.
For the analysis of HT metabolites, samples were thawed and an aliquot of 510 μl
was mixed with 500 μl methanol containing 20 μM daidzein as internal standard.
Compounds were eluted with the following gradient: 0–22 min, isocratic on 12% B;
22–32 min linear from 12% to 35% B; 32–33 min linear from 35% to 90% B; 33–35 min
isocratic on 90%B; 35–36min linear from90% to 12% B and36–50min isocratic on 12% B.
The following MRM transition pairs were used for identiﬁcation: HT, 301→151; HT
glucuronides, 477→301; HT sulfates, 381→301 and daidzein, 253→133. Concentrations
of HT-7-sul were estimated based on the response factor of HT-3′-sul and results are
expressed as HT-3′-sul equivalents.
For the analysis of FA metabolites, samples were thawed and acetic acid and
internal standard DMCA were added to 510 μl of sample to a ﬁnal concentration of 10
mM and 10 μM, respectively. Samples were analyzed as above, except that the gradient
used for elutionwas 0–1min: isocratic on 5% B, 1–10min linear from 5% to 35% B, 10–11
min linear from 35% to 90% B, 11–13 min isocratic on 90% B, 13–14 min linear from 90%to 5% B and 14–30 min isocratic on 5% B. Set MRM transitions used were as follows: for
FA, 193→134; for DHFA, 195→136; for FA-sul, 273→193; for FA-glu, 369→193 and for
DMCA, 207→103.
For SA transport, apical and basolateral samples were analyzed on an HPLC-UV
(Agilent 1200 series) system. An Agilent XDB-C18, 4.6×100mm, 1.8 μmcolumn (Agilent
Technologies, Cheshire, UK) with a ﬂow rate of 0.6 ml/min, injection volume of 5 μl and a 3-
min-long isocratic elutionat35%B. Thepeakareasdeterminedat303nmandat326nmwere
utilized to quantify SA and the DMCA internal standard by comparison to original standards.
Samples for SA analysiswereprepared in the sameway as for the FAmetabolites. All samples
were centrifuged at 17,000g for 5 min before injection.
2.8. Data analysis
For transport experiments, all results are presented as mean values of six biological
replicates analyzed in duplicate and error bars indicate the standard error of the mean
(S.E.M.). Statistical analysis was performed using R and independent samples Student's
t test. Resultswere considered of statistical signiﬁcancewhen Pb.01. For changes in gene
expression and protein analysis, values shown are the mean of three to six biological
replicates ±S.E.M., as indicated in the ﬁgure legends. For analysis of statistical
signiﬁcance, independent samples Student's t test was employed and analysis was
carried out with SPSS Statistics (v22, IBM).
3. Results
3.1. Transport of metabolites across Caco-2 cell monolayers
We investigated the chronic effect (14 days) of butyrate,
propionate, acetate, lactate or their equimolar mixture on the
transport and metabolism of HT (Fig. 1), FA (Fig. 2) and SA (Fig. 3)
in differentiated Caco-2 cells. Tight junction integrity of untreated cells
was conﬁrmed both by TEER measurement and Claudin 1 staining,
indicating uniformmonolayers (Fig. A.2). Compared to untreated cells,
butyrate pretreatment decreased average TEER values by 7% from
1149±23Ω cm2 to 1066±31Ω cm2 (n=36, Pb.001), whereas lactate
increased the resistance by 7% to 1232±25 Ω cm2 (n=36, P=.002).
During the transport experiment, all average TEER values remained
higher than 930 Ω cm2, conﬁrming monolayer integrity [33].
HT and its metabolites were measured relative to authentic
standards in the apical and basolateral compartments. From repre-
sentative chromatograms (Fig. A.1), it is apparent that two isomers of
HT-3′-glu were present in the original standard. These are annotated
as HT-3′-glu 1 and HT-3′-glu 2, corresponding to presumed R and S
enantiomers, and the sum of the two peaks was used. In cells not
treated with SCFA, some HT was transported unchanged through the
cells to the basolateral compartment (87±26 pmol/min), represent-
ing 13% of HT added apically after 60min incubation. Themain phase II
metabolite formed was HT-7-glu, present both in the basal (12.33±
0.57 pmol/min) and apical (3.87±0.07 pmol/min) compartments
accounting in total for 2.4% of the originalHT added apically. ForHT-3′-
glu, the total rate of transport of HT-3′-glu 1 and HT-3′-glu 2 to the
basolateral side was approximately 3-fold higher than efﬂux to the
apical side.
Butyrate treatment increased HT-7-glu levels apically by 12% and
by 23% in the basal compartment, whereas the formation of HT-3′-glu
2 was decreased by 30–40% (n=6, Pb.01). Following propionate
treatment, a higher rate of glucuronidation of HT was evidenced; HT-
3′-glu 1 increased by 52% and HT-7-glu increased by 32%, while in the
basolateral side, HT-7-glu and HT-3′-glu 1 were 42% and 34% higher,
respectively (n=6, Pb.01). In comparison, acetate decreased the
production of HT-3′-glu 2 by 20% (n=6, Pb.01) in both compartments.
All HT phase II conjugates were 13–40% lower in the apical
compartment following lactate treatment, and HT-3′-glu 1 and HT-
3′-glu 2 were also substantially decreased in the basolateral side (n=
6, Pb.01). Transport of sulfated HT conjugates to apical and basal
compartments was comparable in untreated cells, with 1.9±0.03 and
2.53±0.06 pmol/min in the basal and 2.6±0.06 and 2.8±0.1 pmol/
min in the apical compartments, for the 7 and 3′ conjugates,
respectively (Fig. 1). HT-3′-sul efﬂux to the apical direction was
Fig. 1. Transport of HT phase II conjugates in the apical (A and B) and basolateral (C and
D) compartments in Caco-2 cells following treatment with 1 mM individual SCFA,
lactate or a mix for 14 days and incubation with 40 nmol of HT added to the apical
compartment (n=6) for 1 h. Statistically signiﬁcant changes in the concentration of
HT conjugates are indicated (*) when compared to control cells (Control) without
treatment (Pb.01).
Fig. 2. Transport of FA phase II conjugates in the apical (A) and basolateral (B)
compartments in Caco-2 cells following treatment with 1 mM individual SCFA, lactate
or a mix for 14 days and incubation with 1 μmol of FA added to the apical compartment
(n=6) for 1 h. Statistically signiﬁcant changes in the concentration of HT conjugates are
indicated (*) when compared to control cells (Control) without treatment (Pb.01).
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sul and HT-7-sul basolateral transport were stimulated by propionate
treatment. When an equimolar mixture of acetate, propionate,
butyrate and lactate was used, efﬂux of HT-3′-glu 1 to the apical side
was increased.
After incubation of FA with Caco-2 monolayers, some FA was
transported (1.73±0.17 nmol/min) to the basal compartment
accounting for 10.4% of added FA after 1 h. Metabolites were
preferentially transported towards the basal side, with the most
abundant being DHFA and FA-sul (Fig. 2). FA-sul was lower apically
after butyrate treatment, while FA-glu increased by ~40%, but only in
the basal compartment (n=6, Pb.01). In comparison, propionate
treatment increased FA-glu equally in both sides, by 72% in the apical
and 83% in the basolateral. Conversion of FA into DHFA was also
strongly stimulated, resulting in 3.4-fold (n=6, Pb.001) and 4.1-fold
higher concentration of DHFA in the basal and apical compartments,
respectively (n=6, Pb.001), while transport of sulfate conjugates to
the basolateral sidewas favored over efﬂux to the apical compartment.
Acetate had no effect on FA transport and metabolism, while FA-sul
substantially decreased in both compartments (n=6, Pb.01) following
lactate treatment. A mixture of acetate, propionate, butyrate and
lactate led to an increase in FA-glu on the basal side, while
DHFA concentrations were higher in both compartments (n=6,
Pb.01). The latter effect was comparable to the effect of propionate
treatment alone.
Transport of SA to the basolateral side was quite efﬁcient
when compared to HT and FA or their metabolites and accounted for~10% of the original amount added apically within 30 min (Fig. 3). SA
transport was stimulated by butyrate and propionate resulting in a
32% and 21% increase in the basolateral compartment compared to
untreated cells (n=6, P=.003), while acetate and lactate did not affect
SA transport.
3.2. Effect of acetate, propionate, butyrate and lactate on transporters
and UGT1A expression
MCT1 and MCT4 are involved in the transport of SA and FA,
whereas ABCG2 transports HT conjugates. Cellular localization of
these transporters was conﬁrmed in our model by indirect immuno-
ﬂuorescent staining (Fig. A.2). ABCG2wasmainly present at the apical
membrane but also detected in the lateral membrane and in the
nucleus. MCT1 was evident on the apical and lateral membranes and
the nuclear envelope, while MCT4 was speciﬁcally located in the
lateral and basal membranes, in agreement with previous studies.
Changes in MCT1, MCT4 and ABCG2 mRNA after treatment with SCFA
or lactate are shown in Fig. 4. Concomitant changes in MCT1, MCT4,
ABCG2 and UGT protein are shown in Fig. 5. To ensure true
quantiﬁcation of these speciﬁc proteins, all of the antibodies used
were evaluated for linearity and speciﬁcity alone and when multi-
plexed and only used within the validated linear range (Fig. A.3). No
signiﬁcant changes were found in reference loading proteins under
the experimental conditions (Fig. 5).
Butyrate treatment decreasedMCT1mRNA by ~30% (n=4, Pb.005)
while MCT1 protein was increased by ~40% (n=3, P=.01). MCT4
mRNA and protein levels were not affected by butyrate, and although
ABCG2 mRNA decreased (n=4, Pb.005), this was not reﬂected in
Fig. 3. Transport of HT (A), FA (B) and SA (C) by Caco-2 cells to the basolateral
compartment. Cells were treated with 1 mM of SCFA, lactate or a mix for 14 days
followed by the transport experiment. Statistically signiﬁcant changes in concentra-
tions are indicated (*) when compared to control cells (Control) without treatment
(Pb.01).
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for 14 days, gene expression of MCT1 was unchanged whereas MCT4
was increased by ~29% (n=4, Pb.005) without signiﬁcant effects on
MCT1 and MCT4 protein levels. However, both ABCG2 mRNA and
protein levels were lower by ~18% and ~40% respectively (Pb.01),
following chronic propionate exposure. Acetate increased MCT1 (n=
4, P≤.02) andMCT4 (n=4, P≤.005)mRNA levels by ~20%, while ABCG2
mRNA was unaffected; MCT1 protein was decreased by ~30% (n=3,
Pb.005) and UGT1A by ~25% (n=4, P=.02), while MCT4 and ABCG2
were similar to basal levels. Following 14 days of lactate treatment,
MCT1, MCT4 and ABCG2 gene expression was lower by ~20–30%
(Pb.001) while ABCG2 and UGT1A protein levels were ~50% (n=3, P=
.005) and ~30% lower (n=3, P=.009), respectively. An equimolar
mixture of all SCFA and lactate led to 37% higher MCT4 mRNA (n=4,
Pb.001) and 14% lower ABCG2 mRNA (n=4, Pb.001), but these
changes were not reﬂected at the protein level.4. Discussion
The Caco-2 cell line, when grown on a permeable support, displays
morphological and biochemical properties of intestinal enterocytesand expresses drug transporting enzymes simulating the intestinal
membrane barrier [38]. To mimic the in vivo gut maturation process,
we have used a long-term treatment approach during the differen-
tiation stage. We investigated SCFA-induced changes in transport and
metabolism of two abundant microbial metabolites of dietary
(poly)phenols, HT and FA, and we linked these to changes in
transporter and UGT mRNA and protein to explain the mechanism of
the metabolic changes. The multiple interactions observed are
complex and are summarized in Fig. 6. Butyrate is considered a
beneﬁcial fermentation product of dietary ﬁber, and part of the beneﬁt
may derive from its ability to chronically increase the uptake of
hesperetin glucuronide, decreasing efﬂux of (poly)phenol conjugates
back to the gut lumen and increasing uptake of phenolic acids through
up-regulation of the MCT1 transporter.
Chronic butyrate and propionate treatment increased efﬂux of HT-
7-glu to both compartments, in contrast to a decrease following
acetate treatment. As changes were observed in both compartments,
we hypothesized an effect on total glucuronidation of HT rather
than transporters that are mostly direction speciﬁc; in Caco-2 cells,
the enzymes involved are UGT1A1 and UGT1A3 [39]. Acetate
treatment led to 25% lower UGT1A levels in agreement with
transport data; however, butyrate and propionate treatment did
not affect UGT1A. This could be due to a concomitant down-regulation
of other UGT1A isoforms, for example, UGT1A7, 8 or 9, which
are responsible for glucuronidation of HT at the 3′-OH [39], as is
the case upon butyrate treatment. Because of sequence homology
and complex posttranscriptional processing, antibodies for
individual UGT1A family members are not commercially available,
restricting investigation of individual isoforms. Both HT-3′-glu
isomers identiﬁed here have been successfully separated by HPLC
previously [39,40] and shown to have similar phase II metabolism
efﬁciencies upon incubation of HT with human intestinal microsomes
[39], in agreement with our results in the Caco-2 cell model.
Propionate treatment speciﬁcally stimulated glucuronidation of HT-
3′-glu 1, indicating that different enzymes may be involved in the
conjugation to form different isomers.
Apical efﬂux of HT-7-glu is mediated by ABCG2 and, to a lesser
extent, by ABCC2 (MRP2) [27,28]. Both chronic propionate and lactate
treatments down-regulated ABCG2 protein expression, while only
lactate had a signiﬁcant effect on the apical efﬂux of HT-7-glu, leading
us to speculate involvement of another apically located transporter
such as ABCC2. Our hypothesis is further supported by lower apical
efﬂux of both HT-3′-glucuronides upon lactate exposure, since HT-3′-
glu interacts with ABCC2 but lacks afﬁnity for ABCG2 [28].
Lactate also decreased apical efﬂux of both HT sulfates. Reports on
the involvement of ABCG2 on HT-sul transport are inconsistent
[27,29]. Because of apical localization of ABCG2, decreased protein
expression can result in both lower apical efﬂux of substrates, as we
observed for HT sulfates, or increased transport to the basolateral
compartment, as seen for propionate-treated cells. Our results support
a role of ABCG2 in HT-sul transport; however, other transporters
cannot be excluded since both butyrate and acetate treatments also
affected apical efﬂux without an effect on ABCG2.
FA and SA are partially taken up into the cell by apically located
MCT1. Propionate and butyrate strongly enhanced transport of both
compounds, while butyrate increased MCT1 protein, in agreement
with previous work [37]. Basolateral efﬂux of these compounds is by
MCT4, but under our experimental conditions, we did not observe
signiﬁcant changes in the regulation of MCT4. Differences in the
experimental setup could explain this as previously butyrate supple-
mentation was done for 22 days directly after seeding and on both
apical and basolateral sides [37], which would enhance any observed
effects. In our current experiments, SCFA were added for 14 days to
conﬂuent monolayers, and only apically, reﬂecting more closely the
conditions in vivo.
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Fig. 4. mRNA expression of MCT1 (A), MCT4 (B) and ABCG2 (C) in differentiated Caco-2 cells following a 14-day treatment with 1 mM SCFA and lactate measured by ddPCR. Exact copy
numbers of each transporter are shown per nanogram of cDNA. Four biological replicates from two experiments were analyzed in triplicate. TBPwasmultiplexed with each transporter
as housekeeping gene but changeswere also observed for TBP copy numbers. Statistically signiﬁcant changes are indicatedwhen compared to control cells (Control) without treatment
(*P≤.02, **P≤.01, ***P≤.005). Error bars represent S.E.M. C, control; B, butyrate; A, acetate; P, propionate; L, lactate; M, mix.
161E. Van Rymenant et al. / Journal of Nutritional Biochemistry 39 (2016) 156–168Following cellular uptake, FA can be reduced to DHFA, and
reductase activity is strongly stimulated by propionate. In accordance,
the propionate and the mixed SCFA treatments resulted in higher
quantities of DHFA, which can either passively diffuse extracellularly
or be actively transported [41]. Glucuronidation of FA is also mediated
by UGT1A isoforms [34,42]. Based on the transport results, we propose
that propionate stimulates the activity of this enzyme, given the
unilateral increase of FA-glu concentrations. UGT1A protein levels
remained unchanged; however, anymodest changes could bemasked
by the fact that the UGT1A antibody epitopes are raised in an
overlapping area for all UGT1A isoforms as discussed above.
Hydroxycinnamic acids such as FA and their phase II metabolites
were previously found not to interact with ABCG2 or ABCC2 [36].
Inhibition of MRPs previously resulted in decreased transport of FA-
glu andDHFA to the basolateral compartment [41]. ABCC3 (MRP3) and
ABCC6 (MRP6) were suggested as possible candidates [41,43,44]. In
intestinal cells, sulfation of FA to FA-4-O-sulfate occurs via SULT1E1 or
SULT1A1 activity [34]. Here, butyrate decreased apical efﬂux of FA-sul,
and propionate augmented transport of FA-sul to the basolateral
compartment.
Mechanistic data regarding effects of SCFA or lactate on phase II
metabolism were previously very limited [18]. Other physiological
changes caused by SCFA are known to be mediated through
interaction with G-protein-coupled receptors or inhibition of histone
deacetylases [45–47]. For example, in this work, TBP gene expression,
a target of histone deacetylases, was consistently down-regulatedFig. 5. Protein content ofMCT1 (A),MCT4 (B), ABCG2 (C) andUGT1A (D) in Caco-2 cellsmeasure
optimization (Fig. A.3). Pherogram and gel blot (lane) image view of duplicate representativ
denotes nonspeciﬁc interactions of the antibodies with the ﬂuorescence standards used in the
UGT1A and Claudin 1 antibodieswhen run in separate laneswith all other components apart fro
2]. An initial concentration of 1mg/ml of Caco-2whole cell lysate was used forMCT1 andMCT4
(D). Statistically signiﬁcant changes are indicated when compared to control cells (Control) w
butyrate; A, acetate; P, propionate; L, lactate; M, mix.with all SCFA treatments pointing to such a possible mechanism. SCFA
can also modulate expression of conjugating enzymes through PPAR
activation [48,49]. Many endogenous compounds are also known to
modulate UGT and SULT expression by speciﬁcally targetingmembers
of the nuclear receptor superfamily to which PPAR belongs [50–54].
These interactions are clearly complex especially since colonocytes are
exposed to high but varying concentrations of SCFA and lactate in vivo,
which would lead to constantly changing effects on (poly)phenol
absorption and metabolism, depending on dietary composition.
Overall, propionate and butyrate stimulated the transport and
phase II metabolism of HT, FA and SA, resulting in increased
bioavailability in Caco-2 cells. In vivo, consumption of a diet rich in
prebiotics can increase propionate and butyrate production by the
colonic microbiota while decreasing acetate and lactate, thereby
enhancing (poly)phenol bioavailability and reinforcing alleged ben-
eﬁcial effects on gut health. For example, prebiotic ﬁbers such as inulin
shifted the relative contributions of acetate: propionate: butyrate from
65:23:12 to 43:37:20 while brown rice also changed the relative
amounts of the same SCFA in pigs from 68:26:6 to 62:33:5 compared
to white rice consumption [5,55]. Besides ﬁber, (poly)phenols can
themselves act as prebiotics, for example, by inhibiting α-amylase
activity resulting in more resistant starch in the colon [56].
By exposing Caco-2 cells chronically to different SCFAs during the
differentiation phase, we have shown how they may affect (poly)-
phenol bioavailability.Most certainly, these results emphasize that the
microbiome and diet interactions will remain a key component of thed by ProteinSimpleWES. All antibodieswere used in the linear response range following
e samples are shown for treatments where signiﬁcant changes were found (E–H). NS
ProteinSimpleWES system. A representative view of such interactions (NS) is shown for
m sample [F:mock Claudin 1,mockUGT1A and (in F) in-gel blot image view; lanes 1 and
detection (A and B), 0.5 mg/ml for UGT1A (C) and 1.5mg/ml for ABCG2 (andα-tubulin)
ithout treatment (*P≤.02, **P≤.01, ***P≤.005). Error bars represent S.E.M. C, control; B,
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Fig. 6. Summary of HT (A) and FA (B) transport and conjugation in Caco-2 cells. A, acetate; P, propionate; B, butyrate; L, lactate. Changes in measured metabolite levels are indicated by
thick arrows, circled arrows indicate predicted changes in enzymes or transporters and rectangular boxes indicate measured changes inmRNA or protein. Solid lines indicate metabolic
changes; dot-dash lines indicate changes in localization of a metabolite.
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164 E. Van Rymenant et al. / Journal of Nutritional Biochemistry 39 (2016) 156–168Appendix AFig. A.1. Representative chromatograms for HT (metabolites) (A) and FA (metabolites) (B). Dot-dash lines indicate samples and solid lines samples spiked with original standards for
peak identification. 1: HT-7-glu, 2: daidzein (ISTD), 3 and 4: HT-3´-glu (assuming S, R), 5: HT-3´-sul, 6: HT-7-sul (qualitative identification, no standard), 7: HT, 8: FA-glu, 9: FA-sul,
10: DHFA, 11: FA and 12: 3,4-DMCA (ISTD).
Fig. A.2. Indirect immunostaining of related transporters in differentiated Caco-2 cells. Cells were stained with DAPI (blue), membrane marker wheat germ agglutinin (WGA) (green)
and anti-ABCG2 (A), anti-MCT1 (B) or anti-MCT4 (C) (red). Transporters appear orange when colocalizing with WGA and purple when colocalizing with DAPI. Tight junction
formation immunostaining with Claudin 1 (D); cells were stained with DAPI (blue) and Claudin 1 (green).
165E. Van Rymenant et al. / Journal of Nutritional Biochemistry 39 (2016) 156–168
Fig. A.3. Protein detection by ProteinSimple WES system. Antibody validation for protein analysis of MCT1 (A), MCT4 (B), UGT1A (C) and ABCG2 (D). Images consist of pherogram
view, gel blot image (lane view) corresponding to peaks and plotted standard curves indicating linearity of antibodies. Various amounts of total Caco-2 cell lysate were analyzed for
the target and loading control proteins either in the same capillary [MCT1 (A), MCT4 (B) or UGT1A (C)] or separate capillaries [ABCG2 (D)]. NS denotes nonspecific interactions of the
antibodies with the fluorescence standards used in the ProteinSimple WES system.
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